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Cholesterol is a neutral lipid that plays an essential role in the maintenance of the integrity of biologic
membranes and serves as a precursor in the synthesis of many endocrine mediators. It is also synthe-
sized in mammalian cells via the mevalonate pathway. Recent clinical and basic research evidence has
demonstrated a possible linkage of cholesterol to two of the most common diseases of the human
prostate: prostatic cancer and benign prostatic hyperplasia. Accumulation of cholesterol within the lipid
raft component of the cellular plasma membrane may stimulate signaling pathways that promote
prostate tumor growth and progression. In addition, cholesterol-lowering drugs, such as statins, have
exhibited some promising results for these prostatic diseases. This new area of research may provide
insight into the underlying cellular mechanisms leading to prostate hyperplasia, prostate cancer
progression, and potentially novel targets for therapeutic interventions.
Copyright  2011, Taiwan Urological Association. Published by Elsevier Taiwan LLC.
Open access under CC BY-NC-ND license.1. Introduction
More than a century ago, it was reported that crystals of
cholesterol and other fatty acids accumulate in solid tumors.1
Nearly 70 years ago, Swyer demonstrated an increase in the
cholesterol content in prostate adenomas compared with normal
prostatic tissues.2 Since then, studies of human subjects and animal
models support the existence of a relationship between cholesterol
in prostate tissues and secretions with benign and malignant
prostatic neoplasms.3 More recently, epidemiologic evidence
suggests that the modern Western diet, which contains substantial
levels of cholesterol and other fatty substances, promotes prostate
cancer progression.4,5 Consistent with this idea, prolonged inhibi-
tion of the cholesterol synthesis pathway by pharmacologic inter-
vention is associated with a reduction in risk of advanced prostate
cancer.6,7 In addition, epidemiologic and clinical studies have found
positive correlations between a hypercholesterolemic state and
lower urinary tract symptoms (LUTS) that are suggestive of benign
prostatic hyperplasia (BPH).8,9 Therefore, the possible underlying
pathophysiologic mechanisms linking cholesterol and prostatic
diseases have currently become an active area of scientiﬁc research.
Cells maintain their normal structure and function by appro-
priately responding to changes in the surrounding environment.
Transduction of extracellular stimuli is effected from the surfacechool of Medicine, National
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ciation. Published by Elsevier Taiwthrough the plasma membrane by a complex series of interactions
among ligands, receptors, and intracellular signaling mediators.
Cholesterol-enriched membrane microdomains, commonly
referred to as lipid rafts, exist within the lipid bilayer of all
mammalian cells, and they play important roles in signaling from
the cell surface to intracellular pathways. Evidence has implicated
the involvement of lipid rafts in tumor growth and aggressive-
ness,10 so cholesterol-lowering treatments may be a promising
therapeutic modality for prostate cancer and LUTS/BPH. This
review summarizes the current supporting scientiﬁc evidence and
explains the links between cholesterol with two of the most
important prostate diseases: prostatic cancer and LUTS/BPH.2. Cholesterol metabolism
Cholesterol is a prominent component in Western diets. It is
a neutral lipid that plays an essential role in maintaining the
integrity of biologic membranes and also serves as a precursor in
the synthesis of bile acids and many endocrine signaling mediators
(e.g., steroidal hormones). Apart from extrinsic sources, cholesterol
is also synthesized inmammalian cells via the mevalonate pathway
(Figure 1). This pathway also produces a number of other important
metabolic products. For example, isoprene units are precursors in
the synthesis of a variety of molecules, including proteins. Iso-
prenoid modiﬁcation of signaling proteins, such as the Ras and Rho
family members, are essential for proper membrane targeting of
these molecules. Isoprenylated proteins participate in signal
transduction pathways that regulate diverse processes such as the
cell cycle, cell survival mechanisms, and cell motility. Therefore,an LLC. Open access under CC BY-NC-ND license.
Figure 1. The mevalonate pathway in the mammalian cell. CoA ¼ coenzyme A;
HMG ¼ 3-hydroxy-3-methylglutaryl.
Figure 2. Age-matched male fructose-fed and control Wistar rats.
Y.-C. Tong / Urological Science 22 (2011) 97e10298mevalonate products are essential for a wide range of biologic
activities, from hormonal regulation of endocrine target organs to
electron transport. The complexity of products originating from the
mevalonate pathway has confounded studies that focus on poten-
tial relationships between circulating cholesterol levels and pros-
tate cancer incidence or progression, making the results difﬁcult to
interpret.3,10
Similar to cells in other tissues, prostatic cells endogenously
synthesize cholesterol via the mevalonate pathway. Interestingly,the prostate is known to synthesize cholesterol at a rate even
higher than that of the liver.11 However, much of the cholesterol
residing in cell membranes originates from the uptake of circu-
lating lipoproteins.12 Consequently, the cellular cholesterol content
is a balance betweenmetabolicmechanisms intrinsic to the cell and
regulatory functions of cholesterol’s distribution in an organism.
The cholesterol content of cell membranes is under tight homeo-
static regulation, and it involves synthetic pathways in the endo-
plasmic reticulum, transfer of cholesterol from lipoproteins to the
exoplasmic leaﬂet, receptor-mediated internalization, several
intracellular transport mechanisms, and extensive efﬂux from the
cell via secretion of lipoprotein complexes. Evidence shows that
this complex homeostatic mechanism breaks down in cancer as
well as in the aging prostate.33. Evidence connecting hypercholesterolemia and LUTS/BPH
It is well recognized that obesity is a risk factor for the devel-
opment of LUTS.13 Clinical evidence shows its association with
stress urinary incontinence and an overactive bladder.14,15 In
a recent report by the Third National Health and Nutrition Exami-
nation Survey (NHANES III), positive correlations were demon-
strated between markers of metabolic syndrome and LUTS/BPH.9,16
Men classiﬁed as having three or more components of metabolic
syndrome had increased odds for LUTS/BPH [odds ratio (OR): 1.80;
95% conﬁdence interval (CI): 1.11e2.94]. Besides the NHANES III
report, previous clinical observations have also shown a positive
correlation between metabolic syndrome and the prostate. Ham-
marsten and Hogstedt showed that fast-growing BPH is a risk factor
for type 2 diabetes, hypertension, obesity, hypercholesterolemia,
and hyperinsulinemia.8,17 Although BPH is the most common
benign neoplasm in men, its etiology remains unknown. Therefore,
clinical and epidemiologic evidence of a positive correlation
between LUTS/BPH and metabolic syndrome may shed some light
on the etiology of BPH.
In our ongoing studies, we are investigating structural and
functional changes in the prostate associated with metabolic
syndrome using an animal model of fructose-fed rats (Figure 2).
After receiving a high fructose diet for 2e3months, the rats acquire
a metabolic syndrome proﬁle of obesity, insulin resistance, and
hypercholesterolemia.18,19 Preliminary data have shown that the
weight of the prostate signiﬁcantly increases in these rats
compared with those in control rats. Histology suggests glandular
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similar to those reported by Vikram et al. in a study using rats who
were fed a high-fat diet.20 Prostatic enlargement was observed in
those rats. A signiﬁcant increase in cell proliferation markers
conﬁrmed the occurrence of cellular hyperplasia of the prostate.
Enhanced alpha-adrenoceptor-mediated contractions in the pros-
tate indicate augmented contractility of the gland. Taken together,
both human and animal studies offer supportive evidence for
a possible link between hypercholesterolemia and the occurrence
of LUTS/BPH.
4. Epidemiologic studies on the relationship between
cholesterol and prostate cancer
Lifestyle factors play signiﬁcant roles in the clinical aggressive-
ness of prostate cancer. Immigrants to the United States and other
Western nations from Asian countries, where the incidence of
clinical prostate cancer has been low, show a dramatic increase in
clinical prostate cancer.4 This increase in cancer incidence is related
to the time of arrival, with increased cancer risk associated with
early arrival comparedwith individuals whomigrated later in life.21
Because autopsy studies have shown that the incidence of occult
prostate cancer is similar in Asian and Western societies,22,23
studies on immigrants point to an important role of extrinsic
factors, such as diet, in prostate cancer progression. Michaud and
colleagues examined the association of diet and prostate cancer
risk in 51,529 men who contributed detailed dietary data; 1,897
total cases of prostate cancer (excluding stage A1) and 249 meta-
static cancers were identiﬁed.24 Their study concluded that the
intake of red meat and dairy products is related to an increased risk
of metastatic prostate cancer. Although known nutrients such as
calcium and fatty acids may explain most of the dairy association
observed, it appears that a portion of the risk of metastatic prostate
cancer associated with red meat intake remains unexplained.
Many epidemiologic studies have not shown an association
between circulating cholesterol levels and cancer risk.25e28
However, some studies have reported statistically signiﬁcant
correlations between cholesterol intake and cancer risk.29e31 Those
ﬁndings are consistent with the possibility that prolonged
consumption of cholesterol-rich foods might promote the
progression of certain cancer types or cancer growth in selected
tissues. In contrast, there are also studies reporting an inverse
association between cancer incidence and cholesterol levels for
certain neoplasms.32e34 Evidence suggests that this negative rela-
tionship is probably attributable in many cases to the hypo-
cholesterolemic effects of preexisting cancer.35,36 Such a negative
association resulted in studies being designed to identify potential
cancer risks for patients on cholesterol-lowering therapy for
cardiovascular disease. The results of several studies indicated that
treatments for hypercholesterolemia do not increase cancer risk37
and may even lower cancer incidence.38 The Scandinavian Sim-
vastatin Survival Study examined the long-term effects of simvas-
tatin for up to 8 years on cause-speciﬁc mortality in patients with
coronary heart disease. The total number of cancer deaths was 68
(3.1%) in the placebo group and 52 (2.3%) in the simvastatin group
[relative risk (RR), 0.73; 95% CI, 0.05e0.51; p¼ 0.087), and numbers
of noncardiovascular and other deaths were similar in the two
groups.39
5. Cholesterol and cancer cells
Cancer cells de novo synthesize large amounts of fatty acids and
cholesterol irrespective of circulating lipid levels, and they beneﬁt
from this increased lipid synthesis in terms of growth advantage,
self-survival, and drug resistance. Possible mechanisms for theincrease in cholesterol in tumors include: (1) increased absorption
from the circulation40,41; (2) downregulation of low density lipo-
protein (LDL) receptors42; (3) upregulation of the mevalonate
pathway, particularly 3-hydroxy-3-methylglutaryl coenzyme
A (HMG-CoA) reductase42,43; and (4) direct androgen stimulation of
lipogenesis in human prostate cancer cells by increasing tran-
scription of the fatty acid synthase and HMG-CoA reductase
genes.44
Key lipogenic alterations that commonly occur in prostate
cancer include overexpression of the enzyme, fatty acid synthase,
and deregulation of 5-AMP-activated protein kinase.45 Fatty acid
synthase is a key metabolic enzyme that catalyzes the synthesis of
palmitate from the de novo condensation of malonyl-CoA and
acetyl-CoA, and it plays a central role in energy homeostasis by
converting excess carbon intake into fatty acids for storage. The 5-
AMP-activated protein kinase functions as a central metabolic
switch that governs glucose and lipid metabolism. Recent interest
has focused on the potential of targeting metabolic pathways that
are altered during prostate tumorigenesis and progression. Several
small-molecule inhibitors of fatty acid synthase have been
described or are in development for therapeutic use. In addition,
drugs that directly or indirectly induce 5-AMP-activated protein
kinase activation have potential beneﬁts in prostate cancer
prevention and treatment.45
Metastasis to the bone is one clinically important feature of
prostate cancer. Current diagnostic methods cannot predict meta-
static prostate cancer at a curable stage of the disease. Therefore,
identiﬁcation of metabolic pathways involved in the growth of
bone metastases has the potential to improve prostate cancer
prognoses. In a study using metabolomics to study prostate cancer,
signiﬁcant differences were found among bone metastases from
prostate cancer, bone metastases of other cancers, and normal
bone.46 Among metabolites in the bone metastases of prostate
cancer, cholesterol was especially noted. The cholesterol level in
prostate cancer bone metastases was signiﬁcantly increased
(127.30 mg/g vs. 81.06 and 35.85 mg/g in bone metastases of other
origins and normal bone, respectively). Immunohistochemical
staining of prostate cancer bone metastases showed intense
staining of the LDL receptor and variable levels of scavenger
receptor class B type 1 and HMG-CoA reductase in tumor epithelial
cells, indicating the possibility of the inﬂux and de novo synthesis of
cholesterol.46
6. Cholesterol-lowering treatments for BPH and prostate
cancer
Several studies have reported regression induced in dog and
rodent prostates by hypocholesterolemic agents such as the poly-
ene macrolide candicidin.47,48 Human trials with oral candicidin for
BPH in the 1970s reported symptomatic improvement.49,50 Patients
receiving 300 mg/day of candicidin orally showed improved
subjective symptoms in 89.3% of cases compared with 18.2% in
patients treated with a placebo. Residual urine decreased in 85.7%,
and the ﬂow rate improved in more than 89% of cases. More than
one-third of patients treated with candicidin showed an improve-
ment in prostate size compared with none of the patients treated
with the placebo.50 However, in spite of initial encouraging results,
the treatment never became popular because of a lack of long-term
effectiveness.
Attempts to use epidemiologic tools to assess any potential
association of dietary or circulating cholesterol with the risk of
clinical prostate cancer were confronted with signiﬁcant chal-
lenges. Another approach is to determine whether long-term
treatment with cholesterol-lowering drugs affect the incidence
and aggressiveness of prostate cancer. HMG-CoA reductase
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used for many years to treat cardiovascular diseases. HMG-CoA
reductase catalyzes the rate-limiting step in the mevalonate
pathway, and these agents lower cholesterol by inhibiting its
synthesis in the liver and peripheral tissues. The possible anti-
cancer efﬁcacy of statins compared with other methods of lowering
cholesterol may be because these agents lower serum cholesterol
and reduce cholesterol synthesis in peripheral tissues and liver.
This may be of considerable beneﬁt in the case of prostatic
neoplasms because the prostate is reported to synthesize choles-
terol at a rate even higher than that in the liver.11 HMG-CoA-
reductase inhibitors have been demonstrated to exert potent
anticancer effects in model systems. Studies with cell culture
models indicated that statin drugs can inhibit cancer cell growth
and motility, induce apoptosis, and inhibit endothelial cell migra-
tion and tube formation, which are properties associated with
angiogenesis.3 Mevastatin, for example, was shown to inhibit cell
cycle progression in PC-3 human PCa cells by inhibiting cyclin-
dependent kinase (cdk)2 phosphorylation.51 Animal studies have
veriﬁed that this class of agents has a substantial capability to
retard tumor growth, in vivo angiogenesis, and tumor metastasis.52
In general, statins also exhibit a robust selectivity for tumor cells
over normal cells, an essential attribute for successful cancer
therapy.53 Their ability to enhance the efﬁcacy of conventional
chemotherapeutic agents has also been demonstrated.54
Graaf et al. examined 20,000 patients and compared those
taking statins with those taking other cardiovascular-protective
drugs from 1983 to 1998.6 Those investigators found a 20% reduc-
tion in total cancer incidence in the statin cohort, with the largest
reductions in the incidence of prostate and kidney cancers. Patients
who terminated statin therapy returned to a baseline level of risk
within 6 months.
Results of the National Health and Nutrition Examination
Survey9 showed that statin users had a nonstatistically signiﬁcantly
lower prostate-speciﬁc antigen (PSA) than nonusers (0.90 vs.
0.95 ng/mL; p ¼ 0.22), especially in men without comorbidities
(n ¼ 1680; 0.86 vs. 0.99 ng/mL; P ¼ 0.02). In men with comorbid-
ities, statin users had a nonstatistically signiﬁcantly higher PSA
than nonusers (0.91 vs. 0.83 ng/mL; p ¼ 0.14). Men with lowerFigure 3. Model of a lipid raft. Cholesterol and sphingolipids (sphingomyelin and glycosphin
anchored proteins on the external surface. Acylated proteins, such as tyrosine kinases of thecholesterol had lower PSA (bottom vs. top quintile: 0.92 vs. 1.02 ng/
mL; p trend¼ 0.06). This study concluded that statin users andmen
with lower cholesterol may have lower PSA. If this is the case, the
probability of detecting asymptomatic prostate cancer might be
lower at present, but these cases might be more likely to be diag-
nosed at an advanced stage in the future. Therefore, PSA-associated
bias is unlikely to explain the inverse association of statins with
advanced prostate cancer.55
Statin drugs (e.g., pravastatin, lovastatin, and simvastatin)
currently have a sufﬁciently long clinical history so that safety
concerns for many of them can be deﬁnitively evaluated. Because
most statins are now known to be well tolerated by patients,
continued evaluation of these compounds in clinical trials as
potential chemopreventive agents or as adjuvants to standard
therapy is warranted. However, generalization of the anticancer
effectiveness of statins as a group is not advised, because the
different compounds can exhibit signiﬁcantly different activity
proﬁles against tumor cells.53
7. Cholesterol and lipid rafts
In plasma membranes and other intracellular membranes,
cholesterol accumulates in specialized structures known by various
names, such as lipid rafts, detergent-resistant membrane domains,
and detergent-insoluble, glycolipid-enriched complexes. Lipid rafts
are 10e200-nm sphingolipid-cholesterol-rich microdomains
(Figure 3) that compartmentalize cellular processes and can be
stabilized to form larger proteineprotein and proteinelipid
aggregates.56 The stability of rafts is conferred by favorable
molecular interactions between sphingolipids and cholesterol.
Rafts are proposed to serve as platforms to facilitate cellular
signaling, viral entry, cellecell communication, receptor down-
regulation and recycling, and targeted export of proteins and
lipids.57,58 At least two morphologically distinguishable varieties of
lipid rafts exist on cell surfaces. The more familiar type is named
caveolae, and these are identiﬁable in electron micrographs as
striated 50e100-nm invaginations in the plasma membrane.59
Caveolins (caveolin-1, -2, and -3) are structural proteins that
bind cholesterol and are necessary for caveolar formation. Thegolipids) are packed together to form a microdomain. The lipid raft is coated with GPI-
Src family, are attached to the cytoplasmic surface. GPI ¼ glycosylphosphatidylinositol.
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do not contain caveolin proteins and therefore do not form
a recognizable membrane structure identiﬁable on electron
microscopy. Both types of lipid rafts can be biochemically isolated
using similar approaches and have been shown to contain
glycosylphosphatidylinositol-anchored proteins, Src family kinases,
heterotrimeric G protein subunits, and other cell-signaling mole-
cules (e.g., receptor tyrosine kinases).60,61
The ﬁrst evidence that linked lipid rafts to prostate cancer was
the identiﬁcation of caveolin-1 as a marker for aggressive prostate
cancer.62,63 Subsequent studies have indicated caveolin-1 as
a predictor of poor outcomes following surgery in patients with
lymph node-negative prostate cancer.64 Anticaveolin-1 antibodies
have been demonstrated to suppress prostate cancer metastasis in
mice, suggesting that caveolin-1may play a direct role inmetastatic
dissemination.62 Caveolin-1 has also been shown to directly
interact with the androgen receptor and appears to be capable of
participating in mediating androgen-dependent signals in prostate
cancer cells.65 Those ﬁndings suggest the possibility that lipid rafts
may regulate prostate cancer cell growth and survival functions by
compartmentalizing signaling proteins involved in hormonally
responsive or dependent pathways.
Indeed, an emerging area of research is the modiﬁcation of lipid
rafts, which appears to have implications for human health and
disease. Historically, an understanding of how changes in lipid raft
organization alter cellular activity came from cholesterol-depletion
studies. Recently, dietary cholesterol was found to inﬂuence lipid
raft organization, with consequences of alterations in cellular
functions. Future research will hopefully advance our under-
standing of how dietary components can affect cellular functions
through lipid rafts.8. Conclusions
Recent clinical and basic research evidence demonstrates
a possible link of cholesterol to two of themost common diseases of
the human prostate: prostatic cancer and BPH. Accumulation of
cholesterol within the lipid raft component of cellular plasma
membranes may stimulate signaling pathways that promote
prostate tumor growth and progression. This new area of research
may provide insights into the underlying cellular mechanisms
leading to prostatic hyperplasia, prostate cancer progression, and
potentially novel targets for therapeutic interventions.References
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